Vericel downgraded by BTIG Research
$VCEL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BTIG Research downgraded Vericel from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2024 | $57.00 | Buy | Canaccord Genuity |
| 6/20/2024 | $55.00 | Buy | TD Cowen |
| 1/25/2024 | $39.00 → $51.00 | Hold → Buy | Truist |
| 8/8/2023 | $39.00 | Neutral → Buy | BTIG Research |
| 11/10/2022 | Buy → Neutral | BTIG Research | |
| 11/9/2022 | Buy → Hold | Truist | |
| 10/14/2022 | $40.00 | Overweight | Stephens |
| 2/25/2022 | $40.00 → $45.00 | Outperform | SVB Leerink |
Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Total net revenue of $57.9 millionMACI® net revenue growth of 19% to $44.7 millionBurn Care net revenue growth of 66% to $
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% Full-Year Profitability Guidance Raised to 71% Gross Margin and 21% Adjusted EBITDA Margin Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Total net revenue of $52.7
Canaccord Genuity initiated coverage of Vericel with a rating of Buy and set a new price target of $57.00
TD Cowen initiated coverage of Vericel with a rating of Buy and set a new price target of $55.00
Truist upgraded Vericel from Hold to Buy and set a new price target of $51.00 from $39.00 previously
10-Q - Vericel Corp (0000887359) (Filer)
8-K - Vericel Corp (0000887359) (Filer)
8-K - Vericel Corp (0000887359) (Filer)
Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Total net revenue of $57.9 millionMACI® net revenue growth of 19% to $44.7 millionBurn Care net revenue growth of 66% to $
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines i
4 - Vericel Corp (0000887359) (Issuer)
4 - Vericel Corp (0000887359) (Issuer)
4 - Vericel Corp (0000887359) (Issuer)
SC 13G/A - Vericel Corp (0000887359) (Subject)
SC 13G/A - Vericel Corp (0000887359) (Subject)
SC 13G/A - Vericel Corp (0000887359) (Subject)
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010. Ms. Mahoney joins Vericel with more than 20 years of experience across the life sciences and medical device sectors, most recently serving as Chief Human Resources Officer at Abiomed, a global medical device company that was acquired by Johnson & Johnson in December 2022. At Abiomed, Ms. Mahoney led all aspects of HR strategy and
Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member. Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companie
New Independent Board Chair, Dr. Paul K. Wotton, brings 35 years of experience building private and public biopharmaceutical companies with significant business development expertise. Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia. Dr. Paul Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO,
In the latest quarter, 4 analysts provided ratings for Vericel (NASDAQ:VCEL), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Vericel, revealing an average target of $55.5, a high estimate of $57.00, and a low estimate of $55.00. This current average has increased by 0.91% from the previous average price t
Truist Securities analyst Samuel Brodovsky maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $56 to $57.
BTIG analyst Ryan Zimmerman maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $56 to $55.